Viral Vector Service Global Market Report 2025

The viral vector service market size has grown exponentially in recent years. It will grow from $2.04 billion in 2024 to $2.53 billion in 2025 at a compound annual growth rate (CAGR) of 24.4%. Growth during the historic period can be linked to increased government funding for biotechnology research, rising investment by pharmaceutical companies in viral vector manufacturing, greater academic collaboration in gene delivery research, expansion of vaccine development efforts using viral vectors, and growing awareness of advanced therapeutic modalities.

The viral vector service market size is expected to see exponential growth in the next few years. It will grow to $5.99 billion in 2029 at a compound annual growth rate (CAGR) of 24%. Growth in the forecast period can be attributed to the rising outsourcing of viral vector production to CDMOs, heightened focus on expanding large-scale manufacturing capacity, growing demand for efficient vector supply chains, continued expansion of biopharmaceutical manufacturing infrastructure, and increasing adoption of automation in vector production. Key trends anticipated in the forecast period include innovations in modular bioprocessing systems, advancements in digital twin technologies, the development of continuous manufacturing platforms, progress in process analytical technologies (PAT), and the integration of robotics and AI-driven optimization into viral vector production.

The increasing prevalence of infectious diseases is expected to drive the growth of the viral vector services market in the coming years. Infectious diseases are caused by pathogenic microorganisms, such as bacteria, viruses, fungi, or parasites, and can be transmitted directly or indirectly from one person to another. The incidence of infectious diseases is rising, partly due to increased global travel, which facilitates the rapid spread of pathogens across borders. Viral vector services play a critical role in managing infectious diseases by providing reliable platforms for the development of vaccines and gene-based therapeutics. These services enable the efficient delivery of genetic material to target cells, speeding up the development of effective treatments and improving public health responses. For example, in February 2024, the UK Health Security Agency, a UK-based government agency, reported that tuberculosis (a contagious bacterial infection primarily affecting the lungs) cases in England rose to 4,850 in 2023, an increase of 10.7% from 4,380 cases in 2022. As such, the growing prevalence of infectious diseases is driving the expansion of the viral vector services market.

Key companies in the viral vector services market are focusing on innovations in lentiviral vector design and manufacturing, such as fourth-generation vector systems. These advanced systems are engineered to enhance payload capacity, potency, and safety, while also streamlining the development of complex gene therapies. Fourth-generation vector systems are designed with improved safety profiles, optimized gene packaging capabilities, and modular components that enable scalable, plug-and-play manufacturing for cell and gene therapies. For instance, in May 2023, Oxford Biomedica plc, a UK-based viral vector contract development and manufacturing organization (CDMO), launched the TetraVecta system. This system improves vector quality, potency, and packaging efficiency, while also incorporating advanced safety features. It facilitates the creation of high-titer, stable producer cell lines, supporting scalable in vivo gene therapy development. TetraVecta helps streamline the manufacturing process, reducing production timelines and improving overall efficiency for gene therapy programs.

In October 2025, Oxford Biomedica plc acquired RTP Operating LLC for $4.5 million (£3.4 million) to expand its viral vector manufacturing capabilities in the United States. This acquisition allows Oxford Biomedica (OXB) to enhance its commercial-scale viral vector manufacturing capacity, boosting its end-to-end contract development and manufacturing organization (CDMO) services. It also increases its good manufacturing practice (GMP) capacity, supporting both clinical and commercial gene therapy programs for existing and new clients. RTP Operating LLC, a U.S.-based biopharmaceutical company, provides a commercial-scale viral vector manufacturing facility.

Major companies operating in the viral vector service market are Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, FUJIFILM Diosynth Biotechnologies, Danaher Corporation, Sartorius AG, CJ CheilJedang Corp., Charles River Laboratories Inc., Takara Bio Inc., Oxford Biomedica plc, ProBioGen AG, NorthX Biologics Ltd., PackGene Biotech Ltd., Ascend Advanced Therapies Ltd., VectorBuilder Inc., ViroCell Biologics Ltd., Genezen Ltd., Scorpius BioManufacturing Ltd., VGXI Inc., Creative Biogene Ltd., ReiThera Ltd., Tailored Genes Ltd., CoJourney Ltd., InnovaVector Ltd., 3PBIOVIAN Ltd.

North America was the largest region in the viral vector service market in 2024. The regions covered in viral vector service report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the viral vector service market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The viral vector service market research report is one of a series of new reports that provides viral vector service market statistics, including the viral vector service industry global market size, regional shares, competitors with the viral vector service market share, detailed viral vector service market segments, market trends, and opportunities, and any further data you may need to thrive in the viral vector service industry. This viral vector service market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Viral vector service refers to the activities involved in designing, producing, and validating viral vectors used to deliver genes in both research and therapeutic settings. These services support the safe and efficient transfer of genetic material into target cells for developing advanced biologics and gene therapies. They ensure high-quality vector production by following standardized procedures and adhering to regulatory requirements.

The primary service types within viral vector services include process development, manufacturing, quality control, and others. Process development involves the systematic design, optimization, and scaling of a production or manufacturing process to ensure efficiency, consistency, and compliance with quality standards. These services are applied to a range of vector types, such as adenoviral vectors, lentiviral vectors, adeno-associated viral (AAV) vectors, retroviral vectors, and more. They are utilized in applications such as gene therapy, vaccinology, oncology, and others, and serve end users including pharmaceutical and biotechnology companies, research institutions, and additional stakeholders.

The viral vector service market includes revenues earned by entities through vector design, process development, analytical testing, scale-up production, quality control, regulatory support, purification, and fill and finish. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.